A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Part of paid clinical trials in Chandler, Arizona.
- Sponsor
- Loxo Oncology, Inc.
- Study ID
- NCT04965493
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pirtobrutinib — DRUGOral
- Venetoclax — DRUGOral
- Rituximab — DRUGIntravenous (IV)
Study Details
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
Key Dates
- Start date
- Sep 20, 2021
- Status verified
- Jan 2026
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 600 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A (PVR)Fixed duration pirtobrutinib in combination with venetoclax and rituximab
- Active Comparator: Arm B (VR)Venetoclax with rituximab
Primary Outcome Measure
To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B) [ Time Frame: Up to approximately 5 years ]
Locations (41)
Find similar trials in Chandler, AZ
By condition
By specialty
Related Studies
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)PHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina